Home Data Calendar Blog

ADPT

Tables

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Common Stock Value 0.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.00NA0.00NANA
dei: Entity Common Stock Shares Outstanding NANANANANANANANANANANANANANANANANANANANANANA
Weighted Average Number Of Diluted Shares Outstanding 144.70144.40143.51NA142.93142.36141.70NA140.83140.36NANANANANANANANANANANANA
Weighted Average Number Of Shares Outstanding Basic 144.70144.40143.51NA142.93142.36141.70NA140.83140.36NANANANANANANANANANANANA
Weighted Average Number Of Share Outstanding Basic And Diluted NANANANANANA141.70NA140.83140.36138.97NA134.37127.38126.06NA124.2913.2812.89NA12.6212.39
Earnings Per Share Basic -0.35-0.33-0.40-0.28-0.32-0.37-0.44-0.44-0.40-0.35NANANANANANANANANANANANA
Earnings Per Share Diluted -0.35-0.33-0.40-0.28-0.32-0.37-0.44-0.44-0.40-0.35NANANANANANANANANANANANA
Earnings Per Share Basic And Diluted NANANANANANA-0.44-0.44-0.40-0.35-0.29-0.32-0.27-0.26-0.25-0.04-0.11-1.23-1.45-1.00-0.66-1.01

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Revenue From Contract With Customer Excluding Assessed Tax 37.9248.9337.6555.2047.8343.6638.6237.9339.4738.5138.4430.1826.3020.9920.9124.2126.0622.1412.6717.1917.1911.57
Revenues 37.9248.9337.6555.2047.8343.6638.6237.9339.4738.5138.4430.1826.3020.9920.9124.2126.0622.1412.6717.1917.1911.57
Cost Of Goods And Services Sold 19.3517.9118.6816.5914.9113.2213.1914.3614.1910.779.996.226.054.915.345.955.605.734.995.285.365.04
Costs And Expenses 88.8896.7494.8494.3893.2696.16101.6999.5395.7988.2779.7274.4263.3557.9055.5348.4044.1138.2432.7131.3426.3524.88
Research And Development Expense 28.5332.2432.6031.2235.6637.0437.8434.7036.0737.8033.7735.8330.3125.9923.9321.1920.5116.5312.4811.079.789.45
General And Administrative Expense 20.0722.3020.8322.4320.7521.2024.1423.3520.1516.0714.9413.4012.0812.2411.828.198.486.667.006.504.744.63
Selling And Marketing Expense 20.4923.8722.3123.7221.5124.2826.0926.7024.9523.2220.6018.5514.4714.3314.0112.649.108.907.828.076.045.33
Operating Income Loss -50.96-47.82-57.19-39.19-45.43-52.50-63.07-61.60-56.33-49.77-41.28-44.24-37.05-36.91-34.62-24.19-18.05-16.11-20.05-14.14-9.16-13.31
Interest Expense 3.653.603.533.580.65NANANANANANANANANANANANANANANANANA
Interest Paid Net 2.451.882.76NANANANANANANANANANANANANANANANANANANA
Allocated Share Based Compensation Expense 15.3417.3414.6714.2914.1414.1812.8611.8811.6411.208.507.306.506.404.703.403.303.303.003.002.602.40
Profit Loss -50.33-47.81-57.70-40.17-45.32-52.08-62.80-61.36-56.00-49.30-40.64-44.57-36.72-33.53-31.40-20.61-13.95-15.66-18.39-13.27-8.29NA
Net Income Loss -50.30-47.81-57.70-40.13-45.28-52.05-62.74-61.43-55.90-49.30-40.64-44.57-36.72-33.53-31.40-20.61-13.95-15.66-18.39-13.27-8.29-12.49
Comprehensive Income Net Of Tax -49.66-46.80-55.49-38.27-45.45-53.06-66.38-62.58-56.11-49.72-40.90-45.10-37.45-34.70-28.76-20.51-13.76-15.37-18.19-13.18-8.25-12.45

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Assets 717.68764.54791.46856.62884.21806.63858.19923.34992.611033.371072.091116.411095.47854.82874.89912.30917.39601.39NA332.69NANA
Liabilities 356.05368.57367.51392.52396.39288.32304.94319.24341.06340.06346.38373.15320.43324.88323.32341.26331.47323.84NA29.94NANA
Liabilities And Stockholders Equity 717.68764.54791.46856.62884.21806.63858.19923.34992.611033.371072.091116.411095.47854.82874.89912.30917.39601.39NA332.69NANA
Stockholders Equity 361.73396.04424.02464.17487.84518.30553.21603.99651.51693.18725.59743.27775.05529.94551.56571.04585.92-284.37-273.47-258.11-248.08-242.44

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Assets Current 435.24476.81501.33562.15564.38438.57419.12402.75467.03643.73764.96726.91877.36599.52584.65612.69601.36442.30NA180.72NANA
Cash And Cash Equivalents At Carrying Value 88.71109.2494.6190.03217.5576.41114.81139.06122.40184.19173.62123.44497.08365.44212.6996.5874.9448.46NA55.03NANA
Accounts Receivable Net Current 31.2131.5530.9740.0626.5523.7122.5217.4117.1214.1719.7510.0511.867.919.3812.689.267.25NA4.81NANA
Inventory Net 19.4918.9619.8714.4517.3418.7821.0019.2618.2318.6117.4214.0610.7410.5410.529.078.678.00NA7.84NANA
Prepaid Expense And Other Assets Current 13.409.079.799.4412.4112.3512.0413.0216.6312.5313.5214.5419.6810.699.5714.0810.004.04NA3.06NANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Property Plant And Equipment Gross NANANA137.80NANANA121.49NANANA64.07NANANA78.47NANANA31.58NANA
Leasehold Improvements Gross NANANA14.80NANANA14.80NANANA14.80NANANANANANANANANANA
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment NANANA54.35NANANA36.23NANANA24.38NANANA18.12NANANA12.45NANA
Amortization Of Intangible Assets 0.430.420.420.430.430.420.420.430.430.420.420.430.430.420.420.430.430.420.420.430.430.42
Property Plant And Equipment Net 76.7579.3981.2983.4586.6686.8585.9985.2687.8275.2356.3139.6931.1626.8324.9560.3546.5422.30NA19.12NANA
Goodwill 118.97118.97118.97118.97118.97118.97118.97118.97118.97118.97118.97118.97118.97118.97118.97118.97118.97118.97NA118.97NANA
Finite Lived Intangible Assets Net 5.565.996.416.837.267.688.118.538.969.389.8110.2210.6511.0811.5011.9312.3612.78NA13.63NANA
Other Assets Noncurrent 2.983.352.182.062.200.780.870.880.870.720.720.601.001.271.000.780.72NANA0.19NANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Liabilities Current 93.3095.3390.10109.79104.02111.47115.07113.81122.38116.65106.77105.20100.8393.4277.9578.3173.3874.86NA22.80NANA
Long Term Debt Current 3.19NANANANANANANANANANANANANANANANANANANANANA
Accounts Payable Current 4.489.166.338.084.162.725.963.318.256.095.203.245.413.693.904.452.422.94NA1.79NANA
Other Accrued Liabilities Current NANANA1.66NANANA2.82NANANA1.88NANANA0.48NANANA0.55NANA
Accrued Income Taxes Current NANANA0.19NANANA0.39NANANA1.77NANANA2.06NANANA0.11NANA
Accrued Liabilities Current 10.158.368.0412.4210.709.4510.419.3417.0313.5413.4813.165.354.833.804.373.385.02NA2.56NANA
Contract With Customer Liability Current 55.3457.9260.3264.1167.8980.9183.5080.4679.9583.5578.3573.3278.1975.7064.5760.9961.2761.19NA12.70NANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Long Term Debt Noncurrent 126.73NANA125.36NANANANANANANANANANANANANANANANANANA
Minority Interest -0.10-0.07-0.07-0.07-0.030.010.050.110.030.130.13NANANANANANANANANANANA
Operating Lease Liability Noncurrent 91.8294.1896.4998.77100.52102.73104.98106.69108.04103.7795.25104.3342.3742.5036.55NANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Stockholders Equity 361.73396.04424.02464.17487.84518.30553.21603.99651.51693.18725.59743.27775.05529.94551.56571.04585.92-284.37-273.47-258.11-248.08-242.44
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 361.64395.97423.95464.10487.81518.32553.25604.10651.54693.31725.72743.27775.05529.94551.56571.04NANANA-258.11NANA
Common Stock Value 0.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.010.00NA0.00NANA
Additional Paid In Capital 1436.861421.511402.691387.351372.751357.761339.601324.011308.951294.511277.201253.971240.65958.10945.03935.83930.21NANA37.90NANA
Retained Earnings Accumulated Deficit -1074.89-1024.59-976.78-919.08-878.95-833.67-781.63-718.89-657.46-601.55-552.25-511.61-467.04-430.32-396.79-365.48-344.87-330.92NA-295.91NANA
Accumulated Other Comprehensive Income Loss Net Of Tax -0.25-0.89-1.91-4.12-5.97-5.80-4.78-1.140.010.220.630.891.432.153.310.670.570.38NA-0.11NANA
Minority Interest -0.10-0.07-0.07-0.07-0.030.010.050.110.030.130.13NANANANANANANANANANANA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 15.3417.3414.6714.2914.1414.1812.8611.8811.6411.25NANANANANANANANANANANANA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Net Cash Provided By Used In Operating Activities -46.68-23.56-59.15-30.02-42.41-47.06-64.45-53.83-43.44-37.21-58.24-39.84-47.16-31.08-31.61-26.79-30.14-15.97278.30-5.41-11.69NA
Net Cash Provided By Used In Investing Activities 26.1437.3262.98-97.5458.024.7537.6967.21-21.2741.4593.82-340.05-97.25177.49142.7646.68-260.85-45.35-222.1827.635.13NA
Net Cash Provided By Used In Financing Activities 0.021.470.670.01125.523.992.753.282.936.3314.616.25276.046.344.961.75319.55-1.500.120.280.06NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Net Cash Provided By Used In Operating Activities -46.68-23.56-59.15-30.02-42.41-47.06-64.45-53.83-43.44-37.21-58.24-39.84-47.16-31.08-31.61-26.79-30.14-15.97278.30-5.41-11.69NA
Net Income Loss -50.30-47.81-57.70-40.13-45.28-52.05-62.74-61.43-55.90-49.30-40.64-44.57-36.72-33.53-31.40-20.61-13.95-15.66-18.39-13.27-8.29-12.49
Profit Loss -50.33-47.81-57.70-40.17-45.32-52.08-62.80-61.36-56.00-49.30-40.64-44.57-36.72-33.53-31.40-20.61-13.95-15.66-18.39-13.27-8.29NA
Increase Decrease In Other Operating Capital Net 0.06-0.000.01-0.00-0.07NANA0.000.150.000.120.060.000.000.210.060.54NANA-0.02-0.00NA
Increase Decrease In Accounts Receivable -0.330.62-9.0913.512.841.195.110.292.95-5.589.71-1.813.94-1.47-3.283.421.953.19-0.74-7.567.95NA
Increase Decrease In Inventories 0.27-0.076.61-3.03-0.070.551.741.03-0.381.193.363.330.200.021.450.400.660.150.020.73-0.61NA
Share Based Compensation 15.3417.3414.6714.2914.1414.1812.8611.8811.6411.258.487.246.476.374.673.413.333.333.053.052.55NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Net Cash Provided By Used In Investing Activities 26.1437.3262.98-97.5458.024.7537.6967.21-21.2741.4593.82-340.05-97.25177.49142.7646.68-260.85-45.35-222.1827.635.13NA
Payments To Acquire Property Plant And Equipment 2.783.702.922.545.435.303.089.2414.6222.0415.849.374.212.262.962.423.431.523.832.512.19NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Net Cash Provided By Used In Financing Activities 0.021.470.670.01125.523.992.753.282.936.3314.616.25276.046.344.961.75319.55-1.500.120.280.06NA

    2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30
Revenues 37.9248.9337.6555.2047.8343.6638.6237.9339.4738.5138.4430.1826.3020.9920.9124.2126.0622.1412.6717.1917.1911.57
Collaboration Revenue, Immune Medicine Revenue 8.0117.549.1216.2821.3215.0813.7014.5115.4517.6316.06NANANANANANANANANANANA
Immune Medicine Service Revenue, Medicare Reimbursements 0.00NANA0.400.100.000.20NANANANANANANANANANANANANANANA
M R D Service Revenue, Medicare Reimbursements 1.90NANANA1.101.401.20NANANANANANANANANANANANANANANA
Regulatory Milestone Revenue, M R D Revenue NANANA2.000.001.003.000.001.501.507.00NANANANANANANANANANANA
Service, Immune Medicine Revenue 5.245.517.1010.816.567.307.116.868.175.414.05NANANANANANANANANANANA
Service, M R D Revenue 24.6725.8821.4326.1119.9520.2814.8016.5614.3513.9711.34NANANANANANANANANANANA
Genentech Collaboration Agreement 8.0017.509.1016.3020.4013.8012.3014.2015.0017.2015.6016.9012.3012.7010.908.9011.408.506.30NANANA
Immune Medicine Revenue 13.2523.0416.2227.0927.8822.3820.8221.3723.6123.0420.11NANANANANANANANANANANA
M R D Revenue 24.6725.8821.4328.1119.9521.2817.8016.5615.8515.4718.34NANANANANANANANANANANA
Medicare Reimbursements 1.901.301.001.501.101.401.400.401.503.100.80NANANANANANANANANANANA
Revenue From Contract With Customer Excluding Assessed Tax 37.9248.9337.6555.2047.8343.6638.6237.9339.4738.5138.4430.1826.3020.9920.9124.2126.0622.1412.6717.1917.1911.57
Collaboration Revenue, Immune Medicine Revenue 8.0117.549.1216.2821.3215.0813.7014.5115.4517.6316.06NANANANANANANANANANANA
Immune Medicine Service Revenue, Medicare Reimbursements 0.00NANA0.400.100.000.20NANANANANANANANANANANANANANANA
M R D Service Revenue, Medicare Reimbursements 1.90NANANA1.101.401.20NANANANANANANANANANANANANANANA
Regulatory Milestone Revenue, M R D Revenue NANANA2.000.001.003.000.001.501.507.00NANANANANANANANANANANA
Service, Immune Medicine Revenue 5.245.517.1010.816.567.307.116.868.175.414.05NANANANANANANANANANANA
Service, M R D Revenue 24.6725.8821.4326.1119.9520.2814.8016.5614.3513.9711.34NANANANANANANANANANANA
Genentech Collaboration Agreement 8.0017.509.1016.3020.4013.8012.3014.2015.0017.2015.6016.9012.3012.7010.908.9011.408.506.30NANANA
Immune Medicine Revenue 13.2523.0416.2227.0927.8822.3820.8221.3723.6123.0420.11NANANANANANANANANANANA
M R D Revenue 24.6725.8821.4328.1119.9521.2817.8016.5615.8515.4718.34NANANANANANANANANANANA
Medicare Reimbursements 1.901.301.001.501.101.401.400.401.503.100.80NANANANANANANANANANANA

Plots across concepts


IncomeStatement
Operating Income Loss
Expenses
Interest Expense
Balance Sheet
Finite Lived Intangible Assets Net
Assets
Inventory Net
Current Assets
Prepaid Expense And Other Assets Current
NonCurrent Assets
Other Assets Noncurrent
PropertyPlantAndEquipmentNet
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Liabilities
Liabilities Current
Current Liabilities
Accrued Income Taxes Current
Noncurrent Liabilities
Minority Interest
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Income Loss
NetCashProvidedByUsedInOperatingActivities
Net Income Loss
NetCashProvidedByUsedInInvestingActivities
Payments To Acquire Property Plant And Equipment
Shares
Weighted Average Number Of Share Outstanding Basic And Diluted
OperatingLeaseLiability
Operating Lease Liability Current
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
FiniteLivedIntangibleAssets
Finite Lived Intangible Assets Net

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:TypeOfArrangement
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:MRDRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:MedicareReimbursements')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:ImmuneMedicineRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:Revenues
us-gaap:TypeOfArrangement
(None,)
Revenuesus-gaap: Type Of Arrangement
us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:MRDRevenue')
Revenuesus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:MedicareReimbursements')
Revenuesus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:ImmuneMedicineRevenue')
Revenuesus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)
Allocated Share Based Compensation Expenseus-gaap: Income Statement Location
us-gaap:ProfitLoss
us-gaap:StatementEquityComponents
(None,)
Profit Lossus-gaap: Statement Equity Components
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType
('adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrent', None)
Available For Sale Securities Debt Securitiesus-gaap: Information By Category Of Debt Security, us-gaap: Investment Type
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:InformationByCategoryOfDebtSecurity
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Information By Category Of Debt Security
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FinancialInstrument, us-gaap:InformationByCategoryOfDebtSecurity
(None, 'adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrent')
Available For Sale Securities Debt Securitiesus-gaap: Financial Instrument, us-gaap: Information By Category Of Debt Security
us-gaap:PropertyPlantAndEquipmentGross
us-gaap:PropertyPlantAndEquipmentByType
(None,)
Property Plant And Equipment Grossus-gaap: Property Plant And Equipment By Type
us-gaap:FiniteLivedIntangibleAssetsNet
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
(None,)
Finite Lived Intangible Assets Netus-gaap: Finite Lived Intangible Assets By Major Class
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:InformationByCategoryOfDebtSecurity, us-gaap:InvestmentType
('adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrent', None)
Available For Sale Debt Securities Amortized Cost Basisus-gaap: Information By Category Of Debt Security, us-gaap: Investment Type
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:InformationByCategoryOfDebtSecurity
(None,)
Available For Sale Debt Securities Amortized Cost Basisus-gaap: Information By Category Of Debt Security
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:FinancialInstrument, us-gaap:InformationByCategoryOfDebtSecurity
(None, 'adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrent')
Available For Sale Debt Securities Amortized Cost Basisus-gaap: Financial Instrument, us-gaap: Information By Category Of Debt Security
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents
(None,)
Stockholders Equity Including Portion Attributable To Noncontrolling Interestus-gaap: Statement Equity Components
us-gaap:ProfitLoss
us-gaap:StatementEquityComponents
(None,)
Profit Lossus-gaap: Statement Equity Components
us-gaap:Revenues
us-gaap:TypeOfArrangement
(None,)
Revenuesus-gaap: Type Of Arrangement
us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:MRDRevenue')
Revenuesus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:MedicareReimbursements')
Revenuesus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:Revenues
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:ImmuneMedicineRevenue')
Revenuesus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:TypeOfArrangement
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:MRDRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:MedicareReimbursements')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
(None, 'adpt:ImmuneMedicineRevenue')
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service, us-gaap: Type Of Arrangement